Atheroscleroses, Coronary Clinical Trial
— DOLPHINOfficial title:
Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction
Verified date | February 2024 |
Source | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To assess whether vulnerable coronary plaques have more uptake of 68Ga-Dotatate than non-vulnerable plaques.
Status | Completed |
Enrollment | 41 |
Est. completion date | October 6, 2023 |
Est. primary completion date | October 6, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Aged 50 years and older - Underwent CCTA imaging within 78 weeks from the screening visit - Either CAD-RADS 4 or higher or 0/1 on CCTA. - Able to provide written informed consent Exclusion Criteria: - History of chronic kidney disease stage 3b - 5, defined as a CKD-EPI value of < 45 ml/min/1,73m2. - CVD events/revascularization in history - Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator. - Chronic or recent (< 1 month) infections and/or clinical signs of acute infection. - History of auto-immune diseases. - Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices. - Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study. - Elevated liver enzymes (> 2 ULN of liver transaminases), acute liver failure or known liver disease. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Academic Medical Center | Amsterdam |
Lead Sponsor | Collaborator |
---|---|
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in TBRmax | Difference of target to background ratio (TBR)max in the coronary arteries between groups. | 1 day | |
Secondary | Correlation between TBRmax and FAI. | Correlation of TBRmax with fat attenuation index, a specific CCTA parameter of vascular inflammation. | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03606330 -
Systemic, Pancoronary and Local Coronary Vulnerability
|
||
Completed |
NCT05619042 -
Detection of Coronary Artery Calcifications by Whole Blood Transcriptome Analyzed by Artificial InTelligence Algorithms
|
||
Recruiting |
NCT06182683 -
Concurrent OCT and FFR-guided PCI in CAD
|
N/A | |
Not yet recruiting |
NCT05071417 -
Effect Of Semaglutide In Coronary Atheroma Plaque
|
Phase 3 | |
Recruiting |
NCT03894423 -
Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery
|
||
Active, not recruiting |
NCT05567536 -
Long Term Follow-up of Comparison of Clopidogrel vs. Aspirin Monotherapy After Drug-eluting Stent Implantation
|
||
Recruiting |
NCT06083337 -
Vascular Inflammation ReDuction and Perivascular Fat Imaging by Computed Tomography
|
N/A | |
Completed |
NCT04198896 -
The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)
|
||
Completed |
NCT04835467 -
First-In-Human Intracoronary OCT-FLIm In Patients Undergoing PCI
|
N/A | |
Completed |
NCT04125992 -
Distal vs. Forearm Radial Artery Access
|
N/A | |
Completed |
NCT04826354 -
Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease
|
Phase 4 |